Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | NR5A2 | O00482 | 2/20 | 0.82 |
| ▸ | NR5A1 | Q13285 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | FABP3 | P05413 | 1/20 | 0.65 |
| ▸ | SELP | P16109 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | PTAFR | P25105 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | PRKCA | P17252 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31615945 | 1.00 | ALDH1A1 (0.85) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL31469169 | 1.00 | ALDH1A1 (0.85) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL31515814 | 1.00 | ALDH1A1 (0.85) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL31366836 | 1.00 | ALDH1A1 (0.85) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL31381149 | 1.00 | ALDH1A1 (0.85) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL19651935 | 1.00 | ALDH1A1 (0.85) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL236438 | 1.00 | ALDH1A1 (0.85) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL23834444 | 0.99 | NR5A2 (0.83) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL234615 | 0.99 | NR5A2 (0.83) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT | |
| SCHEMBL233018 | 0.99 | NR5A2 (0.83) | ALDH1A1NR5A2NR5A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144803-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | EDEN OPHTHALMIC PTE LTD. (SG) | 2026-05-28 | — | — | US | claimed |
| EP-4743094-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | Eden Ophthalmic Pte Ltd. (SG) | 2026-05-20 | — | — | EP | claimed |
| EP-4627352-A1 | DIAGNOSIS OF METABOLIC CHANGES OF THE LIVER BY WAY OF METABOLIC ANALYSIS OF ERYTHROCYTES BY MASS SPECTROMETRY | Universitätsklinikum Jena (DE) | 2025-10-08 | — | — | EP | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| US-12313634-B2 | Methods for prediction and early detection of diabetes | ZORA BIOSCIENCES OY (FI) | 2025-05-27 | — | — | US | claimed |
| US-12263181-B2 | Phospholipid compositions | MACHAVERT PHARMACEUTICALS LLC (US) | 2025-04-01 | — | — | US | claimed |
| WO-2025024704-A1 | POLYNUCLEOTIDES COMPRISING A MICRO RNA DETARGETING SENSOR AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2025024559-A1 | RNA-BASED SYNTHETIC CIRCUIT FOR PRODUCING ENGINEERED IMMUNE CELLS FOR AN EXTRACORPOREAL CELL THERAPY | STRAND THERAPEUTICS INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2025015046-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | EDEN OPHTHALMIC PTE LTD. (SG) | 2025-01-16 | — | — | WO | claimed |
| CN-118777442-A | Lung cancer lipid marker, application thereof and lung cancer specific diagnostic kit | 复旦大学附属中山医院 | 2024-10-15 | — | — | CN | claimed |
| US-20040254120-A1 | Orally administered small peptides synergize statin activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-16 | — | — | US | claimed |
| EP-1272666-A4 | A FUNCTIONAL ASSAY OF HIGH-DENSITY LIPOPROTEIN | UNIV CALIFORNIA (US) | 2004-09-22 | — | — | EP | claimed |
| US-20040057871-A1 | Functional assay of high-density lipoprotein | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-03-25 | — | — | US | claimed |
| US-20030229015-A1 | Orally administered peptides synergize statin activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-12-11 | — | — | US | claimed |
| US-20030191057-A1 | G-type peptides to ameliorate atherosclerosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-10-09 | — | — | US | claimed |
| US-20030171277-A1 | Orally administered peptides to ameliorate atherosclerosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-09-11 | — | — | US | claimed |
| US-6596544-B1 | Diagnosing atherosclerosis in mammals; obtain tissue sample, incbae with oxidized phospholipid, monitor adjustment in oxidation of phospholipid, absence of adjustment indicates atherosclerosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-22 | — | — | US | claimed |
| US-20030045460-A1 | Orally administered peptides to ameliorate atherosclerosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-03-06 | — | — | US | claimed |
| EP-1272666-A1 | A FUNCTIONAL ASSAY OF HIGH-DENSITY LIPOPROTEIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001075170-A1 | A FUNCTIONAL ASSAY OF HIGH-DENSITY LIPOPROTEIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-10-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144803-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | STARD3, STARD7, PHOSPHO1 | ALDH1A1 4498/4885NR5A2 912/4885NR5A1 167/4885 |
| US-12263181-B2 | Phospholipid compositions | PHOSPHO1, SGMS1, SGMS2 | ALDH1A1 4849/4885NR5A2 4657/4885NR5A1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.